Reporting from ASCO 2023 Annual Meeting, Sebastian Stintzing discusses refined approaches in patient's selection for neoadjuvant chemotherapy alone with selective use of chemoradiation in locally advanced CRC (PROSPECT and NeoCol studies). Regarding precision medicine approaches, he highlights the potential of liquid biopsy in detecting and monitoring RAS wt mCRC (FIRE-4 study) and confirms targeting opportunities for heavily pre-treated patients with HER2-positive, late-stage mCRC (DESTINY-CRC2 study).
Abstracts discussed:
- LBA2: PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
- Abstract 3503: Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.
- Abstract 3507: Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.
- Abstract 3501: Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.